Dissemin is shutting down on January 1st, 2025

Published in

OpenAlex, 2022

DOI: 10.60692/1ac2w-69p48

OpenAlex, 2022

DOI: 10.60692/xfk4d-64a92

Taylor and Francis Group, The Aging Male, 1(25), p. 234-241, 2022

DOI: 10.1080/13685538.2022.2118253

Links

Tools

Export citation

Search in Google Scholar

Updates on androgen replacement therapy and lower urinary tract symptoms: a narrative review

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown

Abstract

Lower urinary tract symptoms (LUTS) are caused by higher tension at the bladder neck level (due to fibrosis or stiffness) or benign prostatic hyperplasia, which causes static obstruction of the bladder outlet. Both forms cause a group of symptoms such as hesitancy, intermittency, weak stream, nocturia, urine frequency, and urgency. Additionally, LUTS (obstructive or irritative symptoms) are common in elderly men with hypogonadism, identified as the reduced testes capability in producing sex steroids and sperm, and are categorized as testosterone deficiency. Even though the mode of action (MoA) of testosterone therapy (TTh) on hypogonadal men needs more researched and understanding, the effectiveness of TTh in the development of male genital organs has been reported in several studies. This review shows the latest updates of TTh in LUTS including potential adverse effects, advantages, and disadvantages.